Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease
- 1 September 1996
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 40 (3), 463-465
- https://doi.org/10.1002/ana.410400319
Abstract
Genetic studies of the frequencies of mutant alleles for coding cytochrome P-450 monooxygenase (CYP 2D6) in Parkinson's disease (PD) patients have been inconsistent. We studied the mutants A and B in 80 strictly defined sporadic PD patients divided into young age onset of the disease (50 years, N = 48). They were compared with 108 controls from the same geographic area. There were no significant differences in allele or genotype frequencies between PD patients and controls. Future genetic studies in PD should focus on other alleles or other areas of the genome.Keywords
This publication has 11 references indexed in Scilit:
- Occurrence of different cancers in patients with Parkinson's diseaseBMJ, 1995
- Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's diseaseThe Lancet, 1992
- Mutant debrisoquine hydroxylation genes in Parkinson's diseaseThe Lancet, 1992
- Genetic susceptibility to Parkinson's diseaseNeurology, 1991
- Debrisoquine oxidation in Parkinson's diseaseActa Neurologica Scandinavica, 1991
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1985
- Metabolic oxidation phenotypes as markers for susceptibility to lung cancerNature, 1984